Evidence map›Paper›PMID 36445965›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2022

The

Kai Mao, Peter Breen, Gary Ruvkun

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Kai MaoDepartment of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114.
Peter BreenDepartment of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114.
Gary RuvkunDepartment of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114.ORCID 0000-0002-7473-8484
Harvard University · US

Funding

CONTROL OF THE C ELEGANS LINEAGE BY HETEROCHRONIC GENESR01GM044619 · NIGMS · MASSACHUSETTS GENERAL HOSPITAL · PI GARY B RUVKUN · 1991 to 2026
$14.5M
GENETIC AND MOLECULAR BASIS OF LONGEVITYR01AG016636 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI GARY B RUVKUN · 1999 to 2026
$12.4M
NIA NIH HHS R01 AG016636NIGMS NIH HHS R01 GM044619
6 · The paper itself

Abstract

Surveillance of

Indexed as

CaenorhabditisAnimalsAntiviral AgentsCaenorhabditis elegansDNA HelicasesMitochondriaAntiviral AgentsDNA HelicasesdetoxificationhealthspanmitochondriaRNAi

Identifiers

PMID36445965
PMCPMC9894117
OpenAlexW4310569281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.